PremiumCompany AnnouncementsNeuren Pharmaceuticals Announces Cessation of Securities via Buy-Back Neuren Pharmaceuticals Updates on Buy-Back Program Neuren Pharmaceuticals Releases 2024 Corporate Governance Statement PremiumCompany AnnouncementsNeuren Pharmaceuticals Updates on Ongoing Buy-Back Program Neuren Pharmaceuticals Advances NNZ-2591 for Newborn Brain Injury Treatment Neuren Pharmaceuticals Updates on Share Buy-Back Progress PremiumCompany AnnouncementsNeuren Pharmaceuticals Updates on Ongoing Share Buy-Back Neuren Pharmaceuticals Updates on Buy-Back Program Neuren Pharmaceuticals Updates on Share Buy-Back Progress